More light for Clinuvel
Tuesday, 23 September, 2008
Clinuvel Pharmaceuticals (ASX: CUV) has begun phase II trials of its photoprotective drug afamelanotide (CUV1657) in patients undergoing photodynamic therapy (PDT).
The trial is being conducted in a Parisian hospital and will extend to multiple health-care centres in France.
The first four of an anticipated 30 patients have been dosed, and results are expected within 12 months.
PDT is used to eradicate pre-malignant lesions of the oesophagus and as a palliative therapy in bile duct cancer. It involves administration of porfimer sodium, a photosensitiser, and a targeted light source.
One side effect is phototoxicity, with patients unable to tolerate UV light. Clinuvel anticipates that afamelanotide may offer a photoprotective effect.
Clinuvel is currently in Phase III trials of CUV1657 in erythropoietic protoporphyria (EPP), or abnormal sun sensitivity.
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
